Biotech financing has returned from its giddy heights at the beginning of the year. Funding declined by 27% from the first quarter's $17 billion to reach >$12 billion, and partnerships deals were hit hardest, declining by almost three-quarters. Even with a biotech market garnering double-digit gains in the second quarter, the amount raised by follow-on financings was off by almost two-thirds. Venture capital and public funding have remained relatively stable; both managed to eke out moderate increases.

Source: Multex, BioCentury
Source: BioCentury, Burrill & Company
Source: BioCentury
Source: BioCentury
Source: BioCentury, Recombinant Capital